Venus Remedies, one of India’s leading research-based pharmaceutical companies, has received Good Manufacturing Practices (GMP) certification from Ukraine for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of its Carbapenem & Oncology production facilities at its unit in Baddi, Himachal Pradesh.
New Delhi, Drug firm Venus Remedies on Monday said it has received good manufacturing practices (GMF) certification from the Saudi drug regulator for its production facilities at Baddi, Himachal Pradesh. The Saudi Food and Drug Authority (SFDA) granted the certification which includes first-time approval for pre-filled enoxaparin syringes and general injection facilities, the company said in a regulatory filing.
MALVERN, Pa.--(BUSINESS WIRE)--Venatorx Pharmaceuticals announced today that it has entered into a Research Collaboration and License Agreement with Roche to discover, characterize and develop new small molecule inhibitors of the Penicillin Binding Proteins (“PBPs”) in Gram-negative bacteria focused on agents active against carbapenem-resistant Enterobacterales (CRE).
Shionogi & Co, Ltd, a Japanese major research-driven pharmaceutical company, announced results from APEKS-NP, an international, double-blind, randomized phase III clinical trial evaluating the efficacy and safety of the investigational antibiotic cefiderocol in patients with nosocomial pneumonia (NP).
OSAKA, Japan & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (hereafter “Shionogi”) announced today that 14 presentations will feature the company’s investigational compounds at IDWeek™ 2018, in San Francisco, October 3-7, 2018.
Entasis Therapeutics has filed to raise up to $86 million through an IPO. The AstraZeneca spinout is seeking the money to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams.